PBI Signs Contract with UTEP for Cancer Treatment Methodology Protocol Shown to Greatly Increase Survival and Prevention of Breast Cancer Metastasis
Premier Biomedical Inc. (OTCQB:BIEI) signed a Patent License Agreement with the University of Texas El Paso (UTEP), covering the cancer treatment process called "CD152-LDMC" which the two entities have been developing in cooperation at the prestigious Border Biomedical Research Center, housed in UTEP's $45-million Bioscience Research Building.Premier Biomedical Develops Patented Application and FDA Filing for Duchenne Muscular Dystrophy
Premier Biomedical, Inc. (OTCQB:BIEI) announced that they have developed and filed a Request for Designation of Duchenne Muscular Dystrophy as a rare disease, preparing the way for a formal "Humanitarian Use Device" (HUD) application for Premier's treatment and potential cure for the disease. A United States Patent application for this treatment methodology was filed in the third quarter of 2014.Premier Biomedical Files Initial FDA Submission for Fibromyalgia Treatment
Premier Biomedical, Inc. (BIEI) announced that they intend to nationally sell an exclusively licensed and patented drug treatment for fibromyalgia. Premier is submitting documents to the Food and Drug Administration to discuss agency requirements for both clinical studies and eventual marketing approval for this patented drug combination. The drug, Feldetrex®, was issued a patent for its unique combination of FDA approved compounds, in October of 2014.Premier Biomedical Files Patent and FDA Application for Ebola Virus Treatment
Premier Biomedical, Inc. (OTCBB: BIEI) announced that they developed an Ebola Virus treatment and filed a related Provisional Patent Application in the fourth quarter of 2014.Premier Biomedical also submitted the Ebola treatment to the Food and Drug Administration (FDA) to outline requirements for investigational testing to determine both safety and efficacy of the technology.Premier Biomedical Announced the Addition of Dr David Vigerust to Their Scientific Advisory Board
Premier Biomedical, Inc. (OTC-BB: "BIEI") announced the addition of Dr David Vigerust to their Scientific Advisory Board effective immediately. Dr Vigerust will report to the Chairman of the Scientific Advisory Board and co-founder of the Corporation, Dr. Mitchell S. Felder.Premier Biomedical, Inc. Acquires Exclusive Licenses for Patent-Pending Medications
Premier Biomedical, Inc. has acquired exclusive licenses for patent-pending medications/medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, and Alzheimer Disease.